BioSpace News Archive

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced its financial results for the first quarter ended March 31, 2020.

AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020.

Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2020 financial results after market close on Thursday, May 21, 2020.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced financial results for the first quarter ended March 31, 2020, and provided an overview of recent developments.

Boston Scientific Corporation announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company’s shelf registration statement.

Abbott’s ID NOW™ is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and where they’re needed

Today, the U.S. Food and Drug Administration is alerting the public to early data that suggest potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19.

TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 8,500,000 shares of common stock at a public offering price of $18.00 per share.

As a first-in-the-world “rapid smart test kit”, the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficacy of different vaccine candidates.